Technical Analysis
-
Trend: The stock is in a clear bearish phase.
-
Indicators:
-
Moving averages (daily): All short-term and long-term MAs indicate a strong sell with at least 12 sell signals and none for buy.
-
RSI (14): 20.9, in deep oversold territory — may hint at a potential technical bounce, but weakness persists.
-
MACD & Bollinger Bands: Bearish momentum, below the mean on both week and month charts; moderate trend strength, underperformance versus the Sensex.
-
-
Price Zone: As of Nov 7, 2025, closing near ₹47. Key support at ₹45–46; resistance at ₹49.50–₹51.
-
Outlook: Only risk-tolerant traders should consider accumulating near ₹45–46 with a tight stop; otherwise, trend remains down until a clear reversal above ₹51.
Fundamental Analysis
-
Q1–Q2 FY26 Results:
-
Revenue: Around ₹425 crore quarterly (7.4% YoY growth); TTM revenue ~₹1,782 crore, positive but slowing.
-
Net Profit: Q4 FY25 saw a 29% YoY drop to ₹20.3 crore due to margin pressures and input costs; yearly bottomline trend still positive but volatile.
-
-
Valuation:
-
P/E ~28.3 (TTM), considered high for current earnings and sector comps.
-
ROCE: 12.8%; Book value per share: ₹41.6; P/B: 2.23 indicates moderate premium.
-
-
Business Mix:
-
Pharma API and branded drugs, diagnostics, and medical devices – expansion in glucometers, growing global APIs, strong R&D.
-
Revenue in medical devices and exports rising, but U.S. exports flat; Europe/Asia strong.
-
-
Balance Sheet: Moderate debt, solid liquidity (current ratio 2.4+), but ROE low at 10.2%.
Upcoming News/Events & Impact
-
Board Meeting – 14 Nov 2025: Likely to review H1 and Q2 FY26 earnings and consider new capex/expansion news; potential for stock movement based on profit outlook.
-
R&D pipeline: New launches in anti-diabetic/orthopedics. Any big US regulatory or export update could act as a near-term trigger.
-
Strategic Investments: ₹200 crore QIP recently raised for expansion in APIs and devices, enhancing future growth prospects.
Disclaimer & Disclosure
-
This analysis is for educational/informational use only.
-
It does not constitute an investment, buy/sell, or financial recommendation.
-
Investors are advised to perform their own due diligence and consult SEBI-registered advisors before investing.
-
Price trends and fundamentals can change with new data; past performance is not indicative of future returns.